An encapsulated bulky abdominal abscess due to amoeba

A proof-of-concept point-of-care test for the serodiagnosis of human amebic liver abscess

Background

Amebic liver abscess (ALA), caused by an extraintestinal invasion of the virulent protozoan Entamoeba histolytica, is important among parasitic causes of morbidity and mortality, especially in the tropics. Clinical symptoms, medical-imaging abnormalities of the liver and serological tests are normally made for supportive diagnosis. Serum-based enzyme-linked immunosorbent assay (ELISA) has been conventionally used for diagnosing ALA but is time-consuming and sophisticated equipment is required. Therefore, we sought to develop a new and rapid innovative point-of-care immunochromatographic test (ICT) that can use whole blood as an alternative to serum-based ELISA. An ICT tool using simulated whole-blood samples was developed for immunoglobulin G antibody detection, and its diagnostic efficiency was evaluated in comparison with serum-based ELISA.

Methods

Both methods were tested to assess their diagnostic performance using a total of 253 serum samples. These came from ALA patients (n = 13), healthy individuals (n = 40), and patients with other diseases (n = 200).

Results

Amebiasis-ICT exhibited 100% (95% confidential interval (CI) [75.3-100.0]) sensitivity and 97.1% (95% CI [94.1-98.8]) specificity, whereas ELISA gave the same sensitivity (100% 95% CI [75.3 -100.0]) and slightly lower specificity (95.8% 95% CI [92.5-98.0]). There were no significant differences in sensitivity and specificity between the two tests (Exact McNemar's test; p > 0.05), with Cohen's kappa agreement 96.44% (κ-value = 0.771, p < 0.001) indicating substantial agreement.

Conclusion

This ICT tool using simulated whole-blood samples has a high possibility of being used with real whole blood. Therefore, since there is no need to separate serum, this can be considered an innovative diagnostic tool to replace serum-based ELISA in clinics and field surveys in remote areas where medical facilities are limited.

Amoebic liver abscess: diagnosis and management of a single case in Guangdong, China

BACKGROUND

Amoebic liver abscess is a hepatic infection due to the invasion of Entamoeba histolytica. This parasitic infection is globally distributed, particularly in tropical and subtropical regions. A remarkable decline in the incidence of amoebic liver abscesses has been observed in recent years thanks to economic and public health progress.

CASE PRESENTATION

This case report describes the symptoms of a 32-year-old male with an amoebic liver abscess. Despite the diagnostic difficulties encountered, favorable outcomes were obtained after the appropriate drainage of the abscess and the appropriate anti-amoebic therapy by the administration of metronidazole.

CONCLUSIONS

The management of amoebic liver abscess requires a meticulous evaluation of the patient's clinical manifestations, the severity of the condition, and the response to therapeutic interventions. Early identification, combined with timely and effective treatment, is essential to reduce the risk of complications and the mortality rate.

CLINICAL TRIAL NUMBER

Not applicable.

Amebic liver abscess by Entamoeba histolytica

Amebic liver abscesses (ALAs) are the most commonly encountered extraintestinal manifestation of human invasive amebiasis, which results from Entamoeba histolytica (E. histolytica) spreading extraintestinally. Amebiasis can be complicated by liver abscess in 9% of cases, and ALAs led to almost 50000 fatalities worldwide in 2010. Although there have been fewer and fewer cases in the past several years, ALAs remain an important public health problem in endemic areas. E. histolytica causes both amebic colitis and liver abscess by breaching the host's innate defenses and invading the intestinal mucosa. Trophozoites often enter the circulatory system, where they are filtered in the liver and produce abscesses, and develop into severe invasive diseases such as ALAs. The clinical presentation can appear to be colitis, including upper-right abdominal pain accompanied by a fever in ALA cases. Proper diagnosis requires nonspecific liver imaging as well as detecting anti-E. histolytica antibodies; however, these antibodies cannot be used to distinguish between a previous infection and an acute infection. Therefore, diagnostics primarily aim to use PCR or enzyme-linked immunosorbent assay to detect E. histolytica. ALAs can be treated medically, and percutaneous catheter drainage is only necessary in approximately 15% of cases. The indicated treatment is to administer an amebicidal drug (such as tinidazole or metronidazole) and paromomycin or other luminal cysticidal agent for clinical disease. Prognosis is good with almost universal recovery. Establishing which diagnostic methods are most efficacious will necessitate further analysis of similar clinical cases.